Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer.

This review examines the evolving treatment landscape for -mutant non-small cell lung cancer (NSCLC), along with the significance of mutations. The development of G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with -mutant NSCLC, overcoming the long-standing challenge of targeting . However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of -mutant NSCLC patients.